Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 21, 2016; 22(47): 10432-10439
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Table 3 Bivariant analysis with steroid-free clinical response according to Mayo score at week 14 of golimumab treatment, n (%)
| Variable | No clinical response n = 8 (24.2) | Clinical response n = 25 (75.8) | P value |
| Age (yr) | 42.71 ± 8.6 | 43.78 ± 14.9 | NS |
| Mo since diagnosis | 56.14 ± 68 | 77.35 ± 87.9 | NS |
| Female sex | 7 (87.5) | 11 (44) | 0.04 |
| Diagnosis < 2 yr | 4 (50) | 17 (70.8) | NS |
| Anti-TNF naïve | 3 (37.5) | 6 (24) | NS |
| > 1 previous anti-TNF | 4 (50.0) | 12 (48.0) | NS |
| Steroid-dependent | 8 (100) | 16 (64.0) | 0.05 |
| Steroid-refractory | 2 (25.0) | 5 (20.0) | NS |
| mean ± SD | |||
- Citation: Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439
- URL: https://www.wjgnet.com/1007-9327/full/v22/i47/10432.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i47.10432